Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-08-17 02:02 UTC

BIOMED PULSE

Monday, August 17, 2026 — Daily Briefing on Longevity, Viruses & New Cures

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in the Democratic Republic of the Congo is now the largest Ebola outbreak ever recorded in the country, with intense, sustained transmission and rapid geographic expansion as of August 14, 2026. [1] The overall mood is high alert on multiple simultaneous fronts: an intensifying hemorrhagic fever crisis in central Africa, fresh food-safety outbreaks at home, and quietly promising longevity science on statin deprescribing and senescence therapy.

🦠 OUTBREAKS & VIRUSES

EBOLA (BUNDIBUGYO VIRUS) — DRC AND UGANDA: RECORD-BREAKING OUTBREAK

  • WHO's August 14 Disease Outbreak News (DON-615) describes the Bundibugyo virus disease (BVD) outbreak in the DRC as entering a phase of "intense transmission," explicitly labeling it the largest Ebola outbreak ever reported in the country and expanding faster than any previous Ebola outbreak. [1]
  • The outbreak began in Mongbwalu Health Zone, Ituri Province, was confirmed on May 14-15, 2026, and has since spread far beyond its origin zone with sustained cross-border transmission into Uganda. [2] [3]
  • As of July 15, 2026 (DON-613), cumulative confirmed cases stood at 2,124 with 828 deaths, reflecting a case fatality rate among confirmed cases approaching 39 percent. [4]
  • As of August 1, 2026 (DON-614), the outbreak had intensified further over the prior two months with continued geographic spread inside the DRC. [5]
  • CDC mobilized an international Ebola response as of May 17, 2026, and enhanced airport Ebola screening has been active at Washington-Dulles International Airport since May 21 and expanded to Atlanta on May 23, 2026. [6] [7] [8]
  • Bundibugyo virus is one of six known species in the genus Ebolavirus; it was first identified in Uganda in 2007 and carries a lower but still serious case fatality rate than Ebola virus (Zaire species). [2]

HANTAVIRUS — M/V HONDIUS CRUISE SHIP, MULTI-COUNTRY

  • WHO's fifth DON (DON-611, July 2, 2026) on the Andes hantavirus (ANDV) outbreak linked to the cruise ship M/V Hondius confirmed additional cases since the May 28 update; the outbreak was originally notified to WHO on May 2, 2026. [9]
  • Earlier reporting (DON-599, May 4, 2026) noted seven cases aboard the 147-passenger-and-crew vessel, including two laboratory-confirmed ANDV and five suspected cases. [10]
  • Andes hantavirus causes hantavirus cardiopulmonary syndrome (HCPS), a severe respiratory illness; ANDV is unique among hantaviruses in having documented person-to-person transmission. [10]
  • CDC provided an updated hantavirus response transcript on June 24, 2026, indicating continued monitoring.

NIPAH VIRUS — KERALA, INDIA

  • WHO DON-609 (June 25, 2026) confirmed a laboratory-confirmed case of Nipah virus (NiV) infection in Kozhikode district, Kerala State, India, in an adult male who developed symptoms May 30 and was hospitalized June 10, 2026, presenting with neurological symptoms.
  • Kozhikode has been the epicenter of previous Kerala NiV outbreaks (2018, 2023); NiV is a bat-borne paramyxovirus with a case fatality rate of 40-75 percent and no licensed treatment.

CYCLOSPORIASIS — TACO BELL, FIVE STATES

  • CDC identified shredded iceberg lettuce served at Taco Bell locations as the source of a Cyclospora cayetanensis outbreak affecting 1,644 sick individuals across five states as of July 17, 2026.
  • The outbreak subsequently expanded to four additional states by July 24, 2026.

SALMONELLA — JALAPEÑOS, MULTISTATE

  • CDC posted a food safety alert on August 5, 2026, warning of a multistate Salmonella outbreak linked to jalapeños.

WEST NILE VIRUS — EARLY SEASON, RECORD CASES

  • CDC on July 1, 2026, flagged an early West Nile virus season with record case counts, urging mosquito bite protection during the Independence Day holiday weekend.

E. COLI — FROZEN BLUEBERRIES

  • CDC warned on July 7, 2026, of an E. coli outbreak linked to frozen blueberries with a product recall issued; consumers told not to eat the recalled product.

YELLOW FEVER — GLOBAL

  • WHO DON-610 (June 24, 2026) reported that, from January 1 to May 26, 2026, six countries reported 79 human yellow fever infections following elevated transmission in the Americas that began in 2025 and carried into 2026.

AVIAN INFLUENZA A(H9N2) — ITALY

  • WHO DON-597 (April 10, 2026) reported a human case of influenza A(H9N2) in an adult male in Italy who had returned from Senegal, confirmed by next-generation sequencing.

MEASLES — BANGLADESH

  • WHO DON-598 (April 23, 2026) reported 19,161 suspected measles cases and 2,897 laboratory-confirmed cases across 58 of 64 districts in all eight divisions of Bangladesh as of early April 2026.

🧬 LONGEVITY & AGING

STATIN DEPRESCRIBING IN ADULTS 75-PLUS: NON-INFERIORITY CONFIRMED

  • The SAGA/SITE multicentre, open-label, pragmatic non-inferiority randomised trial (Lancet Healthy Longevity, Bonnet F et al.) evaluated discontinuation of statins for primary prevention of atherosclerotic cardiovascular disease in adults aged 75 and older.
  • The trial found that stopping statins in this population was non-inferior to continuing them for primary prevention, a finding with major deprescribing implications for the fastest-growing age group.
  • An accompanying commentary (Arya Nezhad S, Nanna MG, Lancet Healthy Longevity) argues the results should shift the default clinical conversation toward stopping rather than continuing statins in older adults on primary prevention.

METFORMIN PLUS LIFESTYLE FOR OBESITY AND FRAILTY IN OLDER ADULTS: DEMFOS TRIAL

  • The DEMFOS randomised controlled trial (Nava MLD, Villareal DT et al., Lancet Healthy Longevity) assessed whether adding metformin to lifestyle intervention improves physical function in older adults with obesity.
  • A linked editorial by Witham MD and McDonald C cautions against inflated expectations, noting that metformin's benefit over lifestyle alone for frailty endpoints remains modest and context-dependent.
  • The DEMFOS finding is relevant to the longevity field because metformin has been widely studied as a geroprotective agent (e.g., the TAME trial) — DEMFOS adds real-world functional-outcome data in an obese elderly population.

SENESCENCE IN OSTEOARTHRITIS: DUAL ANTIOXIDANT-EPIGENETIC APPROACH

  • A study in Bioactive Materials (An X, Jiang Q et al., July 31, 2026) reports a dual-modal antioxidant and epigenetic synergy strategy that attenuates the self-perpetuating senescence cycle in osteoarthritis cartilage, targeting the feedback loop between reactive oxygen species and epigenetic marks that drives cellular aging in joints.

PUNICALAGIN AND BONE MESENCHYMAL STEM CELL SENESCENCE

  • Research published in Regenerative Therapy (Wang Y et al., July 25, 2026) shows that punicalagin, a polyphenol found in pomegranate, alleviates age-related osteoporosis in vivo by inhibiting senescence of bone mesenchymal stem cells via activation of the NRF2/HO-1 antioxidant pathway.

EGFR LOSS AND IMPAIRED FRACTURE HEALING IN AGED MICE

  • A study in Bioactive Materials (Hu Y, Wei Y et al., August 4, 2026) demonstrates that loss of epidermal growth factor receptor (EGFR) activity in skeletal stem and progenitor cells is a key mechanism behind the well-known impairment of fracture healing in aged animals, pointing to EGFR signaling as a potential therapeutic target for bone repair in older patients.

TELOMERE REPAIR AND MISREPAIR IN CANCER CELLS

  • Research in Nucleus (Salmina K, Erenpreisa J et al., July 23, 2026) characterizes how telomeric DNA repair and misrepair unfold in dynamic interactions with PML nuclear bodies and lamin B1 in doxorubicin-treated cancer cells, illuminating mechanisms at the intersection of genomic aging, nuclear architecture, and chemotherapy response.

LYSOSOMAL AMPK ACTIVATION TO TREAT METABOLIC LIVER DISEASE

  • A study in Bioactive Materials (Zhu J et al., July 12, 2026) shows that targeting ROAM1 with UDP-GlcNAc nanosheets selectively activates lysosomal AMPK, resolving metabolic dysfunction-associated steatotic liver disease (MASLD) in preclinical models — linking a core aging-metabolism pathway (AMPK) to a liver condition that is increasingly prevalent with age.

POSITIVE LIFE ORIENTATION AND BLOOD PRESSURE IN OLDER ADULTS

  • A Finnish two-generational cohort study (Lääti A et al., Blood Pressure, August 7, 2026) finds that positive life orientation is associated with lower blood pressure in older adults across cohorts born 20 years apart, suggesting psychological resilience may contribute to cardiovascular longevity independently of birth era.

MINIMALLY PROCESSED DIET AND CANINE EPIGENETIC AGING

  • A pilot study in Veterinary Record Open (Chen A et al., August 5, 2026) reports that a minimally processed, human-grade diet alters canine epigenetic aging markers, using dogs as a translational aging model and raising the possibility that diet quality affects biological age beyond caloric content.

PEPTISLEEP AND SLEEP QUALITY: RANDOMISED PILOT

  • A randomised, placebo-controlled pilot study in Sleep Medicine X (Mohan NM et al., July 28, 2026) evaluated PeptiSleep on sleep modification and biometrics in adults with sleep impairment, finding sleep-related improvements — relevant to longevity given strong evidence linking poor sleep to accelerated aging and premature mortality.

💊 NEW CURES & APPROVALS

OPDIVO (NIVOLUMAB) — BRISTOL MYERS SQUIBB: SUPPLEMENTAL APPROVAL

  • Bristol Myers Squibb received a supplemental approval (SUPPL AP) for Opdivo (nivolumab, BLA 125554), the PD-1 checkpoint inhibitor, expanding its oncology indications; nivolumab blocks the PD-1 receptor on T cells to restore anti-tumor immune activity.

WINREVAIR (SOTATERCEPT-CSRK) — MERCK SHARP DOHME: SUPPLEMENTAL APPROVAL

  • Merck Sharp Dohme received a supplemental approval for Winrevair (sotatercept-csrk, BLA 761363), an activin signaling inhibitor approved for pulmonary arterial hypertension (PAH); sotatercept works by trapping TGF-beta superfamily ligands to rebalance vascular remodeling pathways.

XIGDUO XR (DAPAGLIFLOZIN/METFORMIN HCl) — ASTRAZENECA: SUPPLEMENTAL APPROVAL

  • AstraZeneca AB received a supplemental approval for Xigduo XR (NDA 205649), combining the SGLT2 inhibitor dapagliflozin with metformin hydrochloride for type 2 diabetes management; SGLT2 inhibitors also carry cardiovascular and renal protective indications relevant to aging populations.

SYNJARDY XR (EMPAGLIFLOZIN/METFORMIN HCl) — BOEHRINGER INGELHEIM: SUPPLEMENTAL APPROVAL

  • Boehringer Ingelheim received a supplemental approval for Synjardy XR (NDA 208658), pairing the SGLT2 inhibitor empagliflozin with metformin hydrochloride; empagliflozin has demonstrated cardiovascular mortality benefit in the EMPA-REG OUTCOME trial.

FOSFOMYCIN TROMETHAMINE — NOVITIUM PHARMA: ORIGINAL APPROVAL

  • Novitium Pharma received an original approval (ORIG AP, ANDA 210426) for fosfomycin tromethamine, an antibiotic used for uncomplicated urinary tract infections; the original approval expands generic access to this cell-wall synthesis inhibitor.

HEPZATO (MELPHALAN HCl) — DELCATH SYSTEMS INC: SUPPLEMENTAL APPROVAL

  • Delcath Systems received a supplemental approval for Hepzato (melphalan hydrochloride, NDA 201848), a hepatic delivery system for melphalan used to treat unresectable hepatic metastases from uveal melanoma.

🧪 CLINICAL TRIALS

MK-2214 FOR EARLY ALZHEIMER'S DISEASE — MERCK (NCT07033494)

  • A Phase study of MK-2214 (MK-2214-004, sponsor: Merck) is enrolling participants with early Alzheimer's disease to determine whether MK-2214 slows brain changes associated with AD, including memory loss and communication decline; the trial was updated August 14, 2026.

PEMBROLIZUMAB FOR NEUROLOGICAL LONG COVID — PHASE I (NCT07388550)

  • A Phase I open-label safety trial (PD1-PASC I) is testing pembrolizumab, a PD-1 checkpoint inhibitor, for neurological post-acute sequelae of SARS-CoV-2 (neuro-PASC), including headache, loss of taste/smell, and gait disturbance; the hypothesis is that immune checkpoint blockade may resolve aberrant viral-antigen-driven inflammation in long COVID.

ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE 4 (ADNI4) — NCT05617014

  • ADNI4, a non-randomized longitudinal natural history study, continues to enroll participants across the full Alzheimer's disease spectrum to validate biomarkers and improve clinical trial design, building on ADNI1 through ADNI3; updated August 14, 2026.

KIDNEY FUNCTION ASSESSMENT IN OLDER CHINESE ADULTS — NCT07765134

  • A completed observational cohort study evaluating a comprehensive set of clinical and molecular markers of kidney function — covering glomerular filtration, tubular transport, and kidney endocrine function — in two cohorts of Chinese adults aged 60 and older, aimed at early warning of age-related kidney decline.

EXERCISE DURING CHEMOTHERAPY IN OLDER BREAST CANCER PATIENTS — NCT05025059

  • This clinical trial evaluates the feasibility of structured exercise during chemotherapy in older women (stage I-III breast cancer), building on evidence that physical activity may reduce chemotherapy toxicity risk; updated August 14, 2026.

SAT-3247 FOR DUCHENNE MUSCULAR DYSTROPHY — PHASE 2A (NCT07287189)

  • A Phase 2a randomized, double-blind, placebo-controlled trial of SAT-3247 in ambulatory DMD patients aged 7 to under 10 years is assessing two doses over 12 weeks for optimal dosing, safety, and preliminary efficacy; updated August 14, 2026.

TELEHEALTH FALL PREVENTION FOR OLDER ADULTS IN THE ED — NCT07034287

  • The eGAPcare trial is testing a telehealth modification of the GAPcare fall prevention program in older adults in community emergency departments, incorporating telehealth physical therapy and pharmacy consultation; updated August 14, 2026.

SOCIAL DISCONNECTION AND BRAIN IMAGING STUDY — NCT06705348

  • This study is examining the effect of social connectedness on brain structure and function using MRI, fMRI, PET, and MRS imaging, with relevance to longevity given growing evidence that social isolation accelerates neurocognitive aging; updated August 14, 2026.

📢 PUBLIC HEALTH

SALMONELLA LINKED TO TINY TURTLES — CHILDREN AFFECTED

  • CDC posted an investigation notice on August 16, 2026 (yesterday), warning that tiny turtles — illegal to sell as pets under federal law due to a 1975 ban — are again causing Salmonella infections in young children.

WHO US WITHDRAWAL NOW COMPLETE

  • The United States formally completed its withdrawal from the World Health Organization on January 22, 2026, with CDC confirming the exit; WHO stated on January 24, 2026, that the withdrawal "makes both the United States and the world less safe."
  • WHO noted the withdrawal raises issues being considered by the WHO Executive Board at its February 2 meeting and by the World Health Assembly.

CDC IMMUNIZATION SCHEDULE UPDATE: COVID-19 NOW INDIVIDUAL-BASED

  • As of October 6, 2025, CDC updated its adult and child immunization schedules to apply individual-based decision-making for COVID-19 vaccination and to allow standalone varicella (chickenpox) vaccination in toddlers.

TIMOR-LESTE CERTIFIED MALARIA-FREE BY WHO

  • WHO certified Timor-Leste malaria-free on July 24, 2025, recognizing a nation-wide elimination effort that began shortly after independence in 2002 and sustained control across all districts.

NEW WORLD SCREWWORM RESPONSE

  • CDC activated its Emergency Operations Center for a New World Screwworm (Cochliomyia hominivorax) response on June 12, 2026; screwworm larvae infest living tissue of warm-blooded hosts and were eradicated from the US decades ago, making a re-emergence a significant animal and human health concern.

DEPRESCRIBING FRAMEWORK COMMENTARY

  • Multiple letters in Lancet Healthy Longevity (Hwang CS et al. and Van der Linden LR, July 8 online) argue that deprescribing trials require a rationale-first framework before choosing trial design, cautioning that premature stopping of medications in older adults needs rigorous justification structures.

This briefing is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  2. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  3. Ebola disease caused by Bundibugyo virus – Democratic Republic… — WHO Disease Outbreak News
  4. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  5. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  6. CDC Mobilizes International Response Following Ebola Disease O… — CDC Newsroom
  7. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  8. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  9. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News
  10. Hantavirus cluster linked to cruise ship travel, Multi-country — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260817-02-v58 · 2026-08-17 02:02 UTC · pulse.uzylab.com

Read next